跳至主要内容
临床试验/ISRCTN65282717
ISRCTN65282717已完成未知

A randomised trial of radical radiotherapy in pT1g3 NXM0 bladder cancer

Medical Research Council (MRC) (UK)0 个研究点目标入组 210 人开始时间: 2000年4月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
210

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. A new diagnosis of pT1G3 NXMO tumour or tumours made within 6 months of randomisation. (A prior history of bladder tumours of a lower stage or grade is admissible)
  • 2. No history of urothelial tumours of a higher stage
  • 3. Muscle from the base of tumour is histologically clear
  • 4. Widespread Carcinoma In Situ (CIS) causing severe symptoms is not admissible
  • 5. No clinical, radiological or biochemical evidence of distant metastases
  • 6. No prior therapy with intravesical chemotherapy or BCG other than a single adjuvant treatment
  • 7. No concomitant or previous malignancy other than non-melanomatous skin cancer or cervical intraepithelial neoplasia (CIN)
  • 8. WHO performance status of 0-2
  • 9. Complete resection of all tumours
  • 10. Deemed suitable to undergo radiotherapy and cystoscopy follow-up

排除标准

  • Not provided at time of registration

研究者

发起方
Medical Research Council (MRC) (UK)

相似试验